News | March 19, 2012

Several New Heart Failure Treatments Will Hit Market in Coming Years

March 19, 2012 – Individuals suffering from chronic heart failure (CHF) can look forward to the appearance of many new drug options over the next few years and place hope in a cure through future stem cell therapies, according to a new report by GlobalData.

The new report shows that dissatisfaction with limited CHF therapies, alongside the fast expanding patient population, assures sky-high revenue for pharmaceutical companies willing to develop superior treatments. As a result, numerous molecules are being developed for CHF patients, and stem cell treatment may even offer a cure by transforming the tissue of the heart.

The number of patients seeking treatment for CHF is expected to grow, due to greater health awareness among the general public, increased life expectancy and, consequently, an aging global population, which will be naturally more susceptible to acute heart failure (AHF).

Currently, the only treatment choices for CHF patients are generic drugs, which do not treat the underlying cause of the disease. Drugs such as beta-blockers and diuretics can manage the symptoms of CHF by improving cardiac function, but none can provide disease-modifying mechanisms.

As a result, demand is growing for new treatment options that can present improved safety and efficacy and unique new molecules that can restore or regenerate impaired cardiac muscle cells.

Various pipeline molecules are expected to enter the market within the next few years to provide improved options for CHF patients. GlobalData’s analysis shows that there are 41 molecules under development in the CHF therapeutics pipeline, of which 78 percent are First-in-Class (FIC) and 25 percent are in Phase III.

Several molecules are currently being clinically tested for safety and efficacy in improving cardiac function, and many upcoming drugs include novel mechanisms that could well take over as the standard first-in-line therapy for the treatment and management of CHF.

Stem cell therapy is also capable of improving the CHF treatment pattern. Stem cell therapies currently in development hold the potential to restore cardiac muscle function by regenerating and strengthening heart muscle cells. This will transform patient quality of life and fulfill the market need by providing curative therapy.

The global CHF therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 4 percent from $3.17 trillion in 2006 to $3.85 trillion in 2011. GlobalData analysis suggests that market will grow at a CAGR of 3.1 percent during the forecast period, to reach $4.92 trillion by 2019.

The report is an essential source of information and analysis on the global chronic heart failure therapeutics market. It identifies the key trends shaping and driving the market, and provides insights on the prevalent competitive landscape and the emerging players expected
to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global chronic heart failure therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For more information:

Related Content

News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Overlay Init